BostonGene developed a proprietary analytical platform that integrates whole exome and whole transcriptome sequencing data to provide a comprehensive tumor portrait of the malignant cells and surrounding microenvironment. Using its state-of-the-art molecular testing laboratory, BostonGene combines next generation DNA and RNA sequencing technologies with the most advanced data bioinformatics and analytics to produce a comprehensive report on the unique molecular portrait of the tumor to aid physicians as they identify personalized treatment plans.

BostonGene’s analysis includes:

Whole-exome DNA sequencing

  • Somatic genomic alterations
  • Germline pathogenic alterations
  • Copy number variations
  • Microsatellite instability (MSI)
  • Tumor mutational burden (TMB)
  • Tumor clonal evolution

Whole transcriptome sequencing analysis

  • Gene expression and gene set signatures
  • Validation of clinically relevant aberrations
  • Splice variants
  • Fusion and rearrangement events
  • Anti- and Pro- tumor microenvironment activity and composition
  • T and B cell activity, TCR and BCR repertoire and clonality
  • Analyzing neoantigens from somatic mutations, fusions, recurrent and cancer-testis antigens
  • Presence of oncogenic Viruses

A personalized report is generated for each cancer patient elucidating all clinically relevant genomic and transcriptomic aberrations, which can be utilized to guide treatment decisions.  BostonGene’s proprietary analytical platform generates a report within 14 days of receiving the sample.

Samples are processed at BostonGene’s CLIA registered and MA State Licensed laboratory:  Certification number 22D2182613.

Click here for questions or inquiries about the test.